PEMAZYRE (pemigatinib) tablets. FDA Approved

PEMAZYRE (pemigatinib) tablets can be ordered by patient or doctor, if the drug has not been approved or is not available in your country. Medvitaz Pharma Solutions can help you from India to get best price/cost of PEMAZYRE (pemigatinib) tablets to treat patients with adults with bile duct cancer (cholangiocarcinoma) disease.
Category: .

PEMAZYRE (pemigatinib) tablets, for oral use. Initial U.S. Approval: 2020

PEMAZYRE ™ (pemigatinib) tablets is a prescription medicine used to treat adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. 
INDICATIONS AND USAGE
PEMAZYRE is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s)
DOSAGE FORMS & STRENGTHS
Tablets: 4.5 mg, 9 mg, and 13.5 mg.
Manufactured By: Incyte Corporation
Prescribing Information URL: Click Here

Access to PEMAZYRE ™ (pemigatinib) tablets: All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Pemigatinib (INN), sold under the brand name Pemazyre, is a medication for the treatment of adults with previously treated, unresectable locally advanced or metastatic bile duct cancer (cholangiocarcinoma) with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. Pemigatinib works by blocking FGFR2 in tumor cells to prevent them from growing and spreading.

Pemigatinib belongs to a group of medicines called protein kinase inhibitors. It works by blocking enzymes known as protein kinases, particularly those that are part of receptors (targets) called fibroblast growth factor receptors (FGFRs). FGFRs are found on the surface of cancer cells and are involved in the growth and spread of the cancer cells. By blocking the tyrosine kinases in FGFRs, pemigatinib is expected to reduce the growth and spread of the cancer.

Reviews

There are no reviews yet.

Add a review

neeraj
Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.